Hydroxyurea
Cat. No.：YN250995
| 产品名称: | Hydroxyurea |
| CAS No.: | 127-07-1 |
| Chemical Name: | N-hydroxy-urea |
| Synonyms: | Hydroxycarbamide |
| 分子量: | 76.05 |
| 分子式: | CH₄N₂O₂ |
| SMILES: | O=C(N)NO |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Hydroxyurea 通过抑制核糖核苷酸还原酶抑制DNA合成的细胞凋亡诱导剂。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Madaan, K., Kaushik, D., and Verma, T.Hydroxyurea: A key player in cancer chemotherapyExpert Rev. Anticancer Ther.12(1),19-29(2012)
Yakisich, J.S., Azad, N., Venkatadri, R., et al.Digitoxin and its synthetic analog MonoD have potent antiproliferative effects on lung cancer cells and potentiate the effects of hydroxyurea and paclitaxelOncol. Rep.35(2),878-886(2016)
Krakoff, I.H., Brown, N.C., and Reichard, P.Inhibition of ribonucleoside diphosphate reductase by hydroxyureaCancer Res.28(8),1559-1565(1968)
Almeida, C.B., Scheiermann, C., Jang, J.E., et al.Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease miceBlood120(14),2879-2888(2012)
Gao, W.-Y., Johns, D.G., and Mitsuya, H.Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosidesMol. Pharmacol.46(4),767-772(1994)
Lori, F., and Lisziewicz, J.Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drugClin. Infect. Dis.30(Suppl 2),S193-S197(2000)
Platt, O.S.Hydroxyurea for the treatment of sickle cell anemiaN. Engl. J. Med.358(13),1362-1369(2008)
Boyd, A.S., and Neldner, K.H.Hydroxyurea therapyJ. Am. Acad. Dermatol.25(3),518-524(1991)
